Eyedrops in development for treating conditions such as AMD and Diabetic macular edema

Eye drops are being developed for treating retina that will likely eliminate the need to inject compounds to the back of the eye in conditions such as age-related macular degeneration and diabetic macular edema.

From Scifluor

AMD supplements may not contain ingredients as per AREDS & AREDS2 study recommendations

from NEI

Researchers have found that most best-selling products advertised to slow the progression of age-related macular degeneration do not follow the proven AREDS formula, as per the paper published in the journal Ophthalmology.

Clinical trial for autologous bone marrow stem cells as treatment for AMD & RP shows promise

A phase 1 clinical trial utilizing human bone marrow CD34+ stem cells for patients with retinal vascular occlusion, hereditary or non-exudative age-related macular degeneration (AMD), or retinitis pigmentosa (RP) has shown safety and feasibility.

New treatment potential for babies with Retinopathy of Prematurity

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies such as in Retinopathy of Prematurity and possibly in Diabetic Retinopathy.

Rosemary may have a beneficial effect for patients with Age-related macular degeneration and Retinitis Pigmentosa

Scientists at the Del E Web Center for Neuroscience, Aging, and Stem Cell Research, Sanford-Burnham Medical Research Institute, La Jolla, California, have found that carnosic acid (CA), present in rosemary extract, may potentially have clinical application to diseases affecting the outer retina, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP).

The human eye can see ‘invisible’ infrared light - possible applications in retinal disease diagnoses

All this while, we have been under the impression that our eyes cannot 'see' infrared light. Like the other waves in the invisible spectrum, X-rays and radio waves, infrared light waves were considered to outside our capacity to visualize...that is, until now.

Amarantus Applies for Orphan Drug Designation for MANF in treatment of Retinitis Pigmentosa

Amarantus Bioscience Holdings, Inc., a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and ophthalmological disorders, announced that it has applied to the Food & Drug Administration in the US for Orphan Drug Designation for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP).